Navigation Links
HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Date:6/17/2008

FDA Feedback Supports Innovative Co-development Model

SAN DIEGO, June 17 /PRNewswire/ -- Bio International Convention 2008 (http://www.bio2008.org) -- HUYA Bioscience International (http://www.huyabio.com), the leader in U.S./China pharmaceutical co-development, today announced the outcome of its pre-investigational new drug (IND) consultation meeting with the United States Food and Drug Administration (FDA) for HBI-3000 (Sulcardine sulphate), a promising anti-arrhythmic compound sourced from China. The Agency reviewed and agreed with HUYA's IND-enabling CMC and toxicology plans and high level Phase I plans pending review of non-clinical and clinical data to be submitted as part of the complete IND package. The FDA also agreed to accept data generated in China as 'supportive information' that will support the submission of a U.S. IND and the initiation of a U.S. Phase I trial. HUYA anticipates filing an IND application for HBI-3000 in Q1 2009.

"We're very pleased that the FDA will accept Chinese data to support clinical study design and initiation in the U.S., as this validates our co-development method," said Mireille Gingras, PhD, CEO, HUYA. "We continue to find that in working with China, we can lower the risk and increase the efficiency of drug development in areas of significant unmet need. HUYA is proud to lead the way in co-developing new and important drugs that may save lives."

HBI-3000 is a novel, multi-ion channel blocker for the treatment of atrial or ventricular arrhythmias. In April 2008, HUYA announced the completion of three Phase I protocol studies of HBI-3000 (oral) in China. These clinical studies demonstrated that oral administration of HBI-3000 was well tolerated. The compound has also been tested in an intravenous (IV) formula allowing it to address both in-hospital acute cases and long-term management of chro
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
2. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
3. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Calif. , May 4, 2015  Impax Laboratories, ... filled two key executive leadership roles, appointing  Donna M. ... Deborah M. Penza , as Senior Vice President, Chief ... report to Impax,s President and Chief Executive Officer, ... Donna and Deborah have joined the Impax team," said ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
(Date:5/4/2015)... ANGELES , May 4, 2015  CytRx ... and development company specializing in oncology, today announced ... 1b aldoxorubicin combination studies pairing aldoxorubicin with either ... of gemcitabine or ifosfamide with escalating doses of ... and even at the lowest dose level of ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
... Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim ... prostate cancer drug candidate,CB7630 (abiraterone acetate) was presented ... Meeting, which is currently,taking place in Chicago, Illinois. ... Saturday, June 2nd, as part of the poster,discussion ...
Cached Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 6
(Date:5/4/2015)... Ticket Down is a reputable source for authentic Paul ... South Carolina. Fans of Paul McCartney have to be ... originally kicked off in 2013. The most visited continent of ... performer recently announced that he would be adding additional dates ... in Charlottesville, VA at John Paul Jones Arena on ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... 04, 2015 Unlike some camps, the Nike Middle ... The goal is to educate first and train second, with ... ensures that the young runners are building the knowledge base needed ... of the topics covered include Effort Based Training, Running Heroes, Running ... to be? This is not a camp where kids come ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2
... Abramson, MD, professor of medicine and director of ... hosted a webinar with colleagues from the medical ... together, bench, bedside and the blogosphere to discuss ... RA. The webinar can be viewed at: , ...
... FRIDAY, June 10 (HealthDay News) -- Women are more likely ... a new study contends. A nuclear stress test, also ... blood flow to the heart muscle at rest and during ... heart disease, but it,s expensive and exposes people to radiation. ...
... -- Preschool children with symptoms of attention-deficit/hyperactivity disorder (ADHD) ... an important role in cognitive and motor control, new ... develop ways to treat the common behavioral disorder in ... Kennedy Krieger Institute in Baltimore. In the study, ...
... HealthDay Reporter , THURSDAY, June 9 (HealthDay News) -- The ... new support from a study in mice -- and the ... control weight gain. It,s always a leap to extrapolate ... does open up interesting possibilities. "Humans have basically the ...
... Respirology issues a serious warning of massive ... Dr Ken Takahashi, Acting Director of the WHO Collaborating ... important data on asbestos use in 47 Asian countries ... the highest age-adjusted mortality rates in Asia. This study ...
... - Negative family attitudes can have an adverse effect ... study. Researchers found that although family members, ... mentally ill, they can also be the source of ... recovery. "Negative attitudes of family members have the ...
Cached Medicine News:Health News:NYU Langone rheumatologists share insight with online RA community 2Health News:Women May Be Getting Unneeded Heart Imaging Tests 2Health News:Brain Scan Spots Differences in Tots With ADHD Symptoms 2Health News:Mouse Study Reveals How Smoking Helps Keep People Thin 2Health News:Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next 20 years 2Health News:Mothers Play Important Role in Recovery From Mental Illness 2